 10MG.webp)
GLP-3 (R)
A triple-action research compound targeting GLP receptors. GLP 3 (R) is one of the most advanced metabolic peptides in our catalog.
View Certificate of Analysis →Compound Profile
Pharmaceutical Data Sheet
Mechanism of Action
How GLP-3 (R) Works
Retatrutide (GLP 3 R) is the only investigational compound to simultaneously activate all three key metabolic receptors: GLP-1R for insulin secretion and appetite suppression, GIPR for incretin amplification, and GcgR for hepatic fat oxidation. This tri-agonism produces additive and synergistic metabolic effects beyond any single or dual agonist.
- Suppresses appetite via hypothalamic signaling
- Stimulates glucose-dependent insulin secretion
- Slows gastric emptying
- Reduces hepatic glucose output
- Enhances postprandial insulin release
- Promotes adiponectin secretion
- Counteracts GLP-1 nausea side effects
- Improves beta-cell insulin sensitivity
- Increases hepatic lipolysis and fat oxidation
- Elevates basal metabolic rate
- Reduces hepatic steatosis
- Enhances thermogenesis
By activating GLP-1 receptors, GIP receptors, and glucagon receptors in a balanced ratio, retatrutide achieves complementary effects: GLP-1R reduces appetite and slows gastric emptying; GIPR amplifies insulin response; GcgR drives hepatic lipolysis and energy expenditure — making this the most comprehensive metabolic agonist in development.
N Engl J Med (2023): Phase 2 trial — Retatrutide for obesity and type 2 diabetes.
Preclinical Findings
Research Models
Clinical Data
24.2% Mean Adipose Reduction at 36 Weeks
In the landmark Phase 2 dose-escalation trial, the highest dose cohort (12mg) achieved a mean adipose tissue reduction of 24.2% over 36 weeks — the largest adipose reduction ever reported for any investigational metabolic compound at Phase 2.
Jastreboff AM et al., N Engl J Med (2023); Retatrutide Phase 2 Trial.
Phase 2 RCT, n=338, 36-week follow-up
Research Outcomes
Key Research Success Metrics
Safety Profile
Research Safety Notes
- GI side effects (nausea, vomiting) are dose-dependent and transient during titration
- No serious hypoglycemia events in the Phase 2 monotherapy cohort
- Dose-escalation protocols effectively managed tolerability in clinical trials
- Safety profile consistent with GLP-1 class compounds
- Phase 3 trials ongoing with active safety monitoring
GLP 3 (R) / Retatrutide is an investigational compound in Phase 3 clinical development. All clinical data referenced is from Phase 2 trials. For research use only.
About GLP-3 (R)
A triple-action research compound targeting GLP receptors. GLP 3 (R) is one of the most advanced metabolic peptides in our catalog.
All EVO Labs Research compounds are manufactured to research-grade standards and independently tested by Janoshik Analytical & Kovera Labs. The Certificate of Analysis for this compound includes full HPLC chromatography data, mass spectrometry confirmation, net purity percentage, and net content verification.
Research Use Only
This product is strictly for in vitro research and laboratory use only. Not for human or veterinary consumption. By purchasing, you confirm use in a controlled research setting.
